文献速递妇科

黏液性交界性卵巢肿瘤与浸润性高分化黏液性卵巢癌:特征与结局差异

Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
PubMed 文献 · Gynecol Oncol · 2019-02-20

这项基于监测、流行病学和最终结果计划(1988—2000年)的回顾性人群研究比较了2130例I期黏液性交界性卵巢肿瘤与581例I期高分化黏液性卵巢癌。倾向评分匹配后多变量分析显示,黏液性卵巢癌的10年病因特异性生存率显著低于交界性肿瘤(92.7%对97.5%,调整HR 2.03,P=0.007)。

要点

  • I期黏液性卵巢癌与交界性肿瘤在临床特征和生存上存在明显差异。
  • 匹配后10年病因特异性生存率:黏液性卵巢癌92.7%对交界性肿瘤97.5%(调整HR 2.03,P=0.007)。
  • 黏液性卵巢癌更常见T1c期和更小肿瘤,诊断数量随时间减少。

核心结论

  • I期黏液性交界性卵巢肿瘤与I期浸润性高分化黏液性卵巢癌在临床特征和患者生存方面存在明显差异。

研究设计与样本

  • 回顾性人群研究,分析监测、流行病学和最终结果计划1988年至2000年数据,比较2130例I期黏液性交界性卵巢肿瘤与581例I期高分化黏液性卵巢癌,采用倾向评分匹配和多变量分析评估病因特异性生存。

主要发现

  • 多变量分析显示,黏液性卵巢癌患者更可能年龄较大、居住在美国东部、接受子宫切除术或淋巴结清扫术,且诊断数量随时间减少(均P<0.05)。
  • 黏液性卵巢癌更常见T1c期和更小肿瘤,与交界性肿瘤相比(均调整P<0.05)。
  • 倾向评分匹配后多变量分析显示,黏液性卵巢癌的病因特异性生存显著差于交界性肿瘤(10年率92.7%对97.5%,调整HR 2.03,P=0.007)。
  • 在育龄期、T1a期、大肿瘤和未分期亚组中观察到相似结果(均P<0.05)。

局限性

  • 本研究无法进行集中病理审查,鉴于黏液性交界性卵巢肿瘤与黏液性卵巢癌存在公认的误分类问题,这限制了结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mucinous borderline ovarian tumor (mucinous-BOT) and invasive well-differentiated mucinous ovarian cancer (mucinous-OC) are often histopathologically misclassified. The objective of this study was to examine differences in clinico-pathological characteristics and outcomes of these two entities. METHODS: This is a retrospective population-based study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2000. Stage I mucinous-BOTs and stage I well-differentiated mucinous-OC were compared for patient demographics, tumor characteristics, and outcomes. Propensity score matching and multivariable analysis were used to assess cause-specific survival (CSS). RESULTS: A total of 2130 mucinous-BOT and 581 mucinous-OC cases were examined for analysis. On multivariable analysis, women with mucinous-OC were more likely to be older, Eastern U.S. residents, and have undergone hysterectomy or lymphadenectomy compared to those with mucinous-BOT, and the number of women diagnosed with mucinous-OC decreased over time (all, P < 0.05). Mucinous-OCs were more likely to be stage T1c and have a smaller tumor size as compared to mucinous-BOT (both, adjusted-P < 0.05). After propensity score matching, women with mucinous-OC had significantly poorer CSS compared to those with mucinous-BOT on multivariable analysis (10-year rates: 92.7% versus 97.5%, adjusted-hazard ratio [HR] 2.03, P = 0.007). Similar results were observed among subgroups for reproductive age, stage T1a disease, large tumor, and unstaged cases (all, P < 0.05). CONCLUSION: Stage I mucinous-BOT and stage I invasive well-differentiated mucinous-OC have distinct differences in clinical characteristics and patient survival. The inability to conduct centralized pathology review in our study limits our conclusions given the recognized issue of misclassification of mucinous-BOT and mucinous-OC, but further highlights the importance of making the proper histopathological diagnosis for invasive cancer when the ovarian tumor is of mucinous histology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Machida H, Mandelbaum RS, et al. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecol Oncol. 2019. PMID: 30797590. doi:10.1016/j.ygyno.2019.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。